Trial reportOphthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)2025
Myopia control efficacy of individualised ocular refraction customisation spectacle lenses: A 2-year follow-up study.
Trial report in Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Myopia control efficacy of individualised ocular refraction customisation spectacle lenses: A 2-year follow-up study.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Trial
- Spectacle lenses for control of myopia progression in children.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- Sex specific ocular parameter trajectories during low intensity red light exposure in myopic adolescents in Liaoning China.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo assess second-year myopia progression in children after a 1-year randomised controlled trial of individualised ocular refraction customisation (IORC) spectacle lenses, customised to each eye's peripheral refraction.
methodsA total of 161 children were randomised to wear IORC lenses with high (+4.50 D, IORC-H), medium (+3.50 D, IORC-M) or low (+2.50 D, IORC-L) myopic defocus or single-vision lenses (SV). In year 2, all children received IORC-H, forming the IORC-H1/H2/H3/H4 groups, respectively. An external SV (eSV, n = 42) group was matched to year 2 baseline parameters. Spherical equivalent refraction (SER) and axial length (AL) were measured every 6 months.
resultsCompared with the eSV group (12-month mean [SD] changes: SER -0.56 [0.44] D, AL 0.32 [0.16] mm), all IORC-H intervention groups demonstrated slower progression in year 2 (IORC-H1: -0.17 [0.37] D, 0.19 [0.14] mm; IORC-H2: -0.25 [0.41] D, 0.17 [0.16] mm; IORC-H3: -0.24 [0.36] D, 0.17 [0.14] mm; IORC-H4: -0.22 [0.40] D, 0.14 [0.17] mm; p < 0.05), with no intergroup differences (p > 0.05). Compared with the SV/eSV group, the IORC-H1 group presented 2-year reductions of 0.84 D and 0.38 mm in the SER and AL, respectively (p < 0.001) and exhibited minimal progression during the initial 0-6 months (p < 0.05), followed by constant progression over three subsequent 6-month intervals (p > 0.05).
conclusionsSwitching to IORC-H in year 2 significantly reduced myopia progression and axial elongation. Maximal control efficacy occurred in the first 6 months, with sustained clinically meaningful effects thereafter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.